Claims for Patent: 7,309,486

Summary for Patent: 7,309,486

Title:	HER cancer protocols
Abstract:	The present invention discloses protocols for HER cancers that are also endocrine dependent in a manner that provides dual action by using both HER antibodies and endocrine blockers/downregulators and insures function of S-Phase cytotoxics by administration of endocrines prior to administration of the S-Phase cytotoxic.
Inventor(s):	Zamoyski; Mark (San Jose, CA)
Assignee:
Application Number:	10/295,600
Patent Claims:	1. A method of progressively reducing the size of a tumor or tumors over expressing human epidermal growth factor receptor proteins (HER2 tumors) comprising interlaced administrations of S-Phase specific cell cycle active cytotoxic chemotherapeutic or chemotherapeutics in therapeutically effective amounts to reduce tumor size and HER2 antibodies in therapeutically effective amounts to inhibit tumor regrowth between successive administrations of said cell cycle active cytotoxic chemotherapeutic or chemotherapeutics and for a period of time that does not interfere with the utility of successive administrations of said cell cycle active cytotoxic chemotherapeutic or chemotherapeutics. 2. The method of claim 1 wherein said HER2 antibodies are trastuzumab. 3. The method of claim 1 wherein when said HER2 tumor or tumors are also estrogen, progesterone, or testosterone dependent then estrogen, progesterone or testosterone is administered at a point in time prior to, or concurrent with, or both prior to and concurrent with, administration of said S-Phase specific cell cycle active cytotoxic chemotherapeutic or chemotherapeutics in therapeutically effective amounts to insure progression of said estrogen, progesterone, or testosterone dependent tumor or tumors through the cell cycle. 4. The method of claim 1 wherein when said HER2 tumor or tumors are also estrogen, progesterone, or testosterone dependent then estrogen, progesterone or testosterone blockers or downregulators are administered in conjunction with said HER2 antibodies in therapeutically effective amounts to inhibit progression of said estrogen, progesterone, or testosterone dependent tumor or tumors through the cell cycle and estrogen, progesterone, or testosterone is administered at a point in time prior to, or concurrent with, or both prior to and concurrent with, administration of said S-Phase specific cell cycle active cytotoxic chemotherapeutic or chemotherapeutics in therapeutically effective amounts to insure progression of said estrogen, progesterone, or testosterone dependent tumor or tumors through the cell cycle.

Details for Patent 7,309,486

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-03-29
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-03-29